Shots: The conditional approval is based on the P-II L-MIND study evaluating the safety and efficacy of tafasitamab + lenalidomide in patients with r/r DLBCL who are not eligible for […]readmore
Tags : Lenalidomide
Shots: The first patient has been dosed in the P-III frontMIND study evaluating tafasitamab + lenalidomide + R-CHOP vs R-CHOP alone as a 1L treatment for high-intermediate and high-risk ~880 […]readmore
Shots: The approval is based on P-II L-MIND study assessing Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL Results: ORR (55%); CR […]readmore
Biotech
Regulatory
Janssen’s Darzalex (daratumumab) in Combination with Lenalidomide + Dexamethasone Receive
Shots: The approval is based on P-III MAIA study results assessing Darzalex + Lenalidomide + Dexamethasone (Rd) vs Rd as monothx. in 737 newly diagnosed patients with multiple myeloma ineligible […]readmore
Shots: The approval is based on P-III AUGMENT study results assessing Revlimid + Rituximab (R2) vs rituximab + PBO in patients with previously treated FL & MZL, following its PR […]readmore